# Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer

> **NCT00239304** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (—)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Cisplatin
- **PROCEDURE:** Radiotherapy

## Key facts

- **NCT ID:** NCT00239304
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 40 (—)
- **Last updated:** 2007-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239304, "Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00239304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*